arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

UNITED THERAPEUTICS Corp

UTHR
$488.99 ▼ -8.38 (-1.68%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
87
Health
Excellent
Bullish
auto_awesome

Analytical Summary

UNITED THERAPEUTICS Corp shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $21.7B
Dividend Yield —
Revenue Growth 10.6% ↘
Op. Margin 46.9% ↘
ROIC 16.4% →
FCF / Share $23.49 →
Trailing P/E 16.2x
Price / Book 3.0x
FCF Yield 4.8%
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

19-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$3.18B
↑ +10.6% —
Net Income Profit after all expenses
$1.33B
↑ +11.7% —
Operating Margin Operating profit as % of sales
46.9%
↓ -2.0% 96th
FCF / Share Free cash flow per share
$23.49
↓ -1.7% —
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↑
96
Returns ↑
85
Financial Health ↑
95
Cash Quality ↓
53

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 19 years · 72 quarters